A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
← catalyst calendarNCT05946941 · readout in 91 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
774actual
Sites
199
Countries
Argentina, Australia, Austria +30
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-11 | actual | When the study began enrolling |
| Primary completion | 2026-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-16 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sjögren's Syndrome
Interventions
- Drug: Deucravacitinib — also filed as BMS-986165
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52
measured Baseline, Week 52
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed